u/pavel_kimani

Pointing this one at a pharmacist locally. Eligibility questions have national answers we cannot give.

That shortage notice was national and does not apply where the question is coming from.

Small fix — those two prices are for different pack sizes, which accounts for most of the gap.

Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.

That is a purity figure, not an identity confirmation. Two different tests and only one answers the question asked.

Disagree — that is a rodent study and you are stating it as a human effect. The distance between those is the entire argument.

regulatory status varies by jurisdiction and it has moved recently

Apotheke pricing and pharmacy pricing elsewhere are different systems

regulatory status varies by jurisdiction and it has moved recently

the EMA authorises, member states decide who pays

Have you read the published reimbursement criteria where you are?

EU-wide advice is almost always wrong somewhere

Sent a vial to VendorInvestigate: 99.6% against a claimed 99.0%, with the mass confirming the sequence. Both halves mattered to me.

stability in solution is the practical question nobody asks

Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.

the human evidence is thin and the rodent evidence is not

say which country or the thread is useless

Regulatory classification differs between jurisdictions and has changed in several of them recently. Any answer to a status question needs a place and a date attached.

That claim traces back to a single preclinical paper that says something considerably narrower.

Reconstituted or powder, and how long has it been in solution?

Is that a clinical claim or a preclinical one?

Assumed a prescription would be honoured across the border.

This is the split the whole board depends on. Authorisation is European; payment is national.

short peptides are cheap, which cuts both ways

Yes.

milan_mensah is right about cross-border recognition being narrower than the summaries suggest.

Purity by area percent tells you the sample is homogeneous.

This is the point that should be at the top of every thread here. Identity first.

The variation between pharmacies inside my own country was larger than the variation I had been chasing across the border.

Ask for the theoretical mass alongside the measured one. It is a one-line addition to a certificate and it converts a purity claim into an identity claim.

cross-border prescription rules exist and they are narrower than people think

The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.

Push back: comparing headline prices across countries without normalising pack size is comparing two different quantities.

Right, and regulatory status has genuinely moved in several jurisdictions. Answers from three years ago may be wrong now.